

RESEARCH

Open Access



Changes in total and differential leukocyte counts during the clinically silent liver phase in a controlled human malaria infection in malaria-naïve Dutch volunteers

Marlies E. van Wolfswinkel^{1,2*}, Marijke C. C. Langenberg^{1,3}, Linda J. Wammes², Robert W. Sauerwein⁴, Rob Koelewijn², Cornelus C. Hermsen⁴, Jaap J. van Hellemond² and Perry J. van Genderen¹

Abstract

Background: Both in endemic countries and in imported malaria, changes in total and differential leukocyte count during *Plasmodium falciparum* infection have been described. To study the exact dynamics of differential leukocyte counts and their ratios, they were monitored in a group of healthy non-immune volunteers in two separate Controlled Human Malaria Infection (CHMI) studies.

Methods: In two CHMI trials, CHMI-a and CHMI-b, 15 and 24 healthy malaria-naïve volunteers, respectively, were exposed to bites of infected mosquitoes, using the *P. falciparum* research strain NF54 and the novel clones NF135.C10 and NF166.C8. After mosquito bite exposure, twice-daily blood draws were taken to detect parasitaemia and to monitor the total and differential leukocyte counts. All subjects received a course of atovaquone–proguanil when meeting the treatment criteria.

Results: A total of 39 volunteers participated in the two trials. Thirty-five participants, all 15 participants in CHMI-a and 20 of the 24 volunteers in CHMI-b, developed parasitaemia. During liver stage development of the parasite, the median total leukocyte count increased from 5.5 to 6.1 × 10⁹ leukocytes/L (p = 0.005), the median lymphocyte count from 1.9 to 2.2 (p = 0.001) and the monocyte count from 0.50 to 0.54 (p = 0.038). During the subsequent blood stage infection, significant changes in total and differential leukocyte counts lead to a leukocytopenia (nadir median 3.3 × 10⁹ leukocytes/L, p = 0.0001), lymphocytopenia (nadir median 0.7 × 10⁹ lymphocytes/L, p = 0.0001) and a borderline neutropenia (nadir median 1.5 × 10⁹ neutrophils/L, p = 0.0001). The neutrophil to lymphocyte count ratio (NLCR) reached a maximum of 4.0. Significant correlations were found between parasite load and absolute lymphocyte count (p < 0.001, correlation coefficient – 0.46) and between parasite load and NLCR (p < 0.001, correlation coefficient 0.50). All parameters normalized after parasite clearance.

Conclusions: During the clinically silent liver phase of malaria, an increase of peripheral total leukocyte count and differential lymphocytes and monocytes occurs. This finding has not been described previously. This increase is followed by the appearance of parasites in the peripheral blood after 2–3 days, accompanied by a marked decrease in total leukocyte count, lymphocyte count and the neutrophil count and a rise of the NLCR.

Keywords: Controlled Human Malaria Infection, *Plasmodium falciparum*, Leukocyte count, Lymphocyte count, Lymphocytopenia, Neutropenia, Monocytes, Neutrophil to lymphocyte count ratio, Liver phase

*Correspondence: mvanwolfswinkel@gmail.com

¹ Institute for Tropical Diseases, Harbour Hospital, Rotterdam, The Netherlands

Full list of author information is available at the end of the article

Background

Controlled Human Malaria Infection (CHMI) is a well-established clinical model that was developed for the evaluation of candidate malaria vaccines and drugs [1]. In this model, healthy volunteers are infected by malaria sporozoites via exposure to the bites of infected mosquitoes or via inoculation by needle and syringe [2]. CHMI studies have traditionally been performed using the *Plasmodium falciparum* strain NF54, which is thought to originate from Africa [3]. More recently, the clones NF135.C10, and NF166.C8, originating from *P. falciparum* strains from Cambodia and Guinea, respectively, have been added to the CHMI portfolio [4–6]. In the present study, the CHMI model is used to study total and differential leukocyte count changes and their ratios during the liver phase and blood phase of malaria.

Changes in total and differential leukocyte count during *P. falciparum* infection have been described in both clinical studies and CHMI studies previously. In clinical studies, both in endemic countries and in patients with imported malaria [7–10], the most pronounced change is the decrease of peripheral lymphocytes. Lymphocytopenia has been observed in 45 to 63% of patients with an imported *P. falciparum* infection, but was less prominent in patients with some degree of anti-malarial immunity [11, 12]. In a recent large cross-sectional study on leukocyte count changes in returning travellers, malaria was the second most common cause of absolute lymphocytopenia [13]. Differential leukocyte count changes have also been studied in patients with imported malaria. The neutrophil-to-lymphocyte count ratio (NLCR), which was introduced by Zahorec et al. as a parameter of systemic inflammation in critically ill surgical and medical patients [14], correlated with parasitaemia and normalized after parasite clearance in patients with imported malaria [11, 12]. One study showed correlations between parasitaemia and both the monocyte to lymphocyte count ratio (MLCR) and neutrophil to monocyte count ratio (NMCR) [11].

In CHMI studies, decreases in total leukocyte count, neutrophil count and lymphocyte count have been described during the blood phase [15–20], but could not evaluate leukocyte changes during liver stages of the parasite life cycle.

In the present study, the changes of differential leukocyte counts and their ratios were monitored during the liver phase and the development of detectable blood parasitaemia in a group of healthy non-immune volunteers in the CHMI model using the NF54, NF166.C8 and NF135.C10 *P. falciparum* clones.

Methods

Study design

The present study was performed using two Controlled Human Malaria Infection studies, CHMI-a and CHMI-b [4]. Healthy malaria-naïve adult Dutch volunteers were recruited

at the Harbour Hospital, Rotterdam, after signing informed consent. In CHMI-a, fifteen subjects were randomly allocated to three groups of $n = 5$, to be infected by bites of five mosquitoes per subject carrying either the NF54 strain of *P. falciparum*, the NF135.C10 clone or the novel NF166.C8 clone. In CHMI-b, 24 subjects were randomly allocated to six groups of $n = 4$, to bites by one, two or five mosquitoes carrying either NF135.C10 or NF166.C8. From day 5 after exposure, subjects were seen in clinic twice daily for registration of vital parameters and adverse events and for venous blood draws for thick blood smear, qPCR, and a wide range of laboratory parameters including differential leukocyte counts. *Plasmodium falciparum* parasitaemia was quantified by qPCR as described before [21]. In CHMI-a, subjects were treated with atovaquone–proguanil 1000/400 mg daily for 3 days upon their first positive thick blood smear, defined as ≥ 2 parasites per 225 high-powered fields (equivalent to 0.5 μL blood). In CHMI-b, subjects were treated with the same regimen as soon as 2 consecutive blood samples were positive by qPCR, defined as > 500 parasites/mL. This change in treatment initiation between the two studies was implemented to minimize safety risks following a cardiac serious adverse event in a previous study [15, 22]. Daily thick blood smears and qPCR were continued after treatment until complete clearance of asexual parasites.

Data selection

This study focused on leukocyte count changes during the liver stage and blood stage of the malaria infection in the participants of CHMI-a and CHMI-b. Data from the measurements taken during the liver phase in both studies were combined. However, the described differences in methodology regarding the initiation of treatment in both studies did not permit combination of blood phase CHMI-a and CHMI-b data. For this phase, the data of only CHMI-b were used, as in this study the subjects who remained qPCR negative, but received the same treatment as the parasitaemic subjects, could be used as a negative control group to exclude an effect of the atovaquone–proguanil on the evaluated parameters.

Statistical analysis

To determine whether the parameters of interest changed over time a Friedman test was performed. Next, a more detailed analysis of the timing of these changes was done using a linear model. Correlations were tested with the Spearman's rank-order correlation. Data were not normally distributed and given as median (interquartile range) unless stated otherwise.

Definitions

Leukocytopenia Leukocyte count $< 4.0 \times 10^9/\text{L}$;

Lymphocytopenia L y m p h o c y t e count $< 1.0 \times 10^9/L$;

Neutropenia Neutrophil count $< 1.5 \times 10^9/L$.

Day of treatment (DT) The day the subject started a 3-day course of atovaquone–proguanil, directly upon meeting the treatment criteria. The days from 2 days before until 3 days after this day are named DT – 2 to DT + 3.

Liver phase The subjects who eventually developed parasitaemia were regarded as being in the liver phase on day 5 and 6 of the study protocol, when the peripheral blood samples of all subjects were still qPCR negative.

Detectable blood parasitaemia Detectable blood parasitaemia is defined as qPCR positive, a method with a detection limit of 50 parasites per mL.

Results

Development of parasitaemia and phases of the infection

In CHMI-a, all participants developed parasitaemia, with a median prepatent period of 8 days (range 6.5–10.5 days), determined by thick blood smear, upon which curative treatment was initiated. As determined retrospectively, all subjects were still qPCR negative on day 5 and 6 of the study protocol. Of the 24 participants in CHMI-b, twenty (83%) developed parasitaemia. The median prepatent period as determined by qPCR was 7 days (range 7–9 days) and the median time between exposure and the day the treatment criteria were met (hereafter called day of treatment [DT]) was 8 days (range 7–11 days).

For CHMI-b, the data from 2 days before DT (DT – 2) until 3 days after DT (DT + 3) were synchronized on DT (Fig. 1). On DT – 2, four subjects had a positive qPCR, all with a low parasitaemia (385–713 parasites/mL) and did not meet the treatment criteria at that moment. The number of parasitaemic subjects increased to nine subjects on DT – 1. The median parasite load on DT, when all patients met the treatment criteria, was 6265 parasites per mL. Hereafter the parasite load declined to 1099 on DT + 1 and 100 parasites per ml on DT + 2.




Fig. 1 Changes in total and differential leukocyte counts in the 20 subjects who developed malaria in CHMI-b. The data are shown as medians (dots) and interquartile ranges (whiskers). The data from DT – 2 until DT + 3 were synchronized on DT

Changes in differential leukocyte counts and count ratios during the liver phase

All 35 subjects who developed detectable parasitaemia in CHMI-a and CHMI-b were still qPCR negative at day 5 and 6 of the study protocol, and the infection was therefore regarded as being in the liver phase [23]. During this phase an increase of the total leukocyte count, lymphocyte count and the monocyte count was observed in the 35 subjects who developed parasitaemia later on in CHMI-a and CHMI-b. Changes in neutrophil count and the differential cell count ratios were not significant. No significant changes were observed in the four subjects who remained qPCR negative in CHMI-b. No differences between the total or differential leukocyte counts were

found between subjects infected with NF54 strain, the NF135.C10 clone or the NF166.C8 clone (Table 1).

Changes in differential leukocyte counts and count ratios after the liver phase

In the group of twenty parasitaemic subjects in CHMI-b, highly significant changes in the total leukocyte count and differential cell counts of neutrophils, lymphocytes and monocytes were observed in the days before DT and during treatment (Table 2 and Fig. 1). These changes were not seen in non-parasitaemic individuals (Additional file 1: Table S1 and Additional file 2: Figure S1). Of interest, both parasitaemic and non-parasitaemic individuals received anti-malarial treatment, thus excluding

Table 1 The course of differential leukocyte counts and their ratios during the liver phase in the subjects who develop malaria

	Leukocytes × 10 ⁹ /L	Neutrophils × 10 ⁹ /L	Lymphocytes × 10 ⁹ /L	Monocytes × 10 ⁹ /L	NLCR	MLCR	NMCR
CHMI-a (n = 15)							
Baseline	5.8 (5.3–6.5)	3.1 (2.9–3.3)	1.9 (1.9–2.3)	0.51 (0.48–0.58)	1.6 (1.4–1.7)	Baseline	5.8 (5.3–6.5)
Day 5	6.8 (6.1–7.3)	3.6 (2.9–4.0)	2.3 (2.0–2.5)	0.55 (0.46–0.63)	1.6 (1.4–1.8)	Day 5	6.8 (6.1–7.3)
Day 6	6.9 (5.8–7.6)	3.2 (2.7–4.1)	2.4 (1.9–2.7)	0.55 (0.49–0.58)	1.3 (1.1–1.9)	Day 6	6.9 (5.8–7.6)
p value	0.105	0.721	0.140	0.208	0.623	p value	0.105
CHMI-b (n = 20)							
Baseline	5.1 (4.9–6.1)	2.8 (2.5–3.1)	1.6 (1.5–2.0)	0.48 (0.35–0.60)	1.8 (1.1–2.0)	0.3 (0.2–0.3)	5.8 (4.7–8.3)
Day 5	5.7 (5.4–7.2)	3.1 (2.2–3.6)	2.0 (1.7–2.5)	0.49 (0.43–0.60)	1.3 (1.0–2.1)	0.2 (0.2–0.3)	5.9 (4.8–7.2)
Day 6	6.0 (5.3–6.9)	3.0 (2.4–3.8)	2.2 (1.9–2.4)	0.53 (0.46–0.65)	1.4 (1.1–1.8)	0.2 (0.2–0.3)	5.3 (4.6–7.1)
p value	0.051	0.195	0.004	0.012	0.165	0.196	0.848
Combined (n = 35)							
Baseline	5.5 (5.0–6.2)	2.9 (2.6–3.2)	1.9 (1.6–2.2)	0.50 (0.38–0.60)	1.7 (1.3–2.0)	0.3 (0.2–0.3)	6.1 (4.8–8.4)
Day 5	6.1 (5.5–7.2)	3.3 (2.5–3.7)	2.2 (1.8–2.5)	0.50 (0.43–0.54)	1.5 (1.1–1.9)	0.2 (0.2–0.3)	6.1 (4.9–8.1)
Day 6	6.1 (5.5–7.0)	3.0 (2.6–3.9)	2.2 (1.9–2.6)	0.54 (0.47–0.62)	1.4 (1.1–1.8)	0.2 (0.2–0.3)	5.7 (4.8–7.2)
p value	0.005	0.413	0.001	0.038	0.121	0.368	0.971

The data of CHMI-a and CHMI-b are shown separately and combined

Data in this table are not normally distributed and shown as median (interquartile range). p values in this table were derived from Friedman tests

Table 2 The course of differential leukocyte counts and their ratios in the 20 subjects who develop malaria in CHMI-b

	Leuko- cytes × 10 ⁹ /L	Neutro- phils × 10 ⁹ /L	Lympho- cytes × 10 ⁹ /L	Mono- cytes × 10 ⁹ /L	NLCR	MLCR	NMCR	Parasite load parasites/mL
Baseline	5.1 (4.9–6.1)	2.8 (2.5–3.1)	1.6 (1.5–2.0)	0.48 (0.35–0.60)	1.8 (1.1–2.0)	0.3 (0.2–0.3)	5.8 (4.7–8.3)	N/A
DT – 2	5.8 (5.4–6.8)	3.0 (2.3–3.7)	2.1 (1.9–2.4)	0.49 (0.43–0.61)	1.4 (1.0–1.7)	0.2 (0.2–0.3)	5.6 (4.3–6.8)	0 (0–0)
DT – 1	5.8 (5.3–6.6)	2.9 (2.6–3.5)	2.0 (1.5–2.3)	0.55 (0.46–0.65)	1.4 (1.1–2.1)	0.3 (0.2–0.3)	5.2 (4.5–6.7)	0 (0–374)
DT	5.6 (4.8–6.1)	3.1 (2.8–3.6)	1.6 (0.9–2.0)	0.53 (0.40–0.58)	2.2 (1.4–3.8)	0.4 (0.4–0.5)	6.4 (5.0–8.0)	6265 (1306–12,152)
DT + 1	4.4 (3.9–4.7)	3.0 (2.5–3.2)	0.8 (0.6–1.1)	0.44 (0.30–0.60)	4.0 (2.2–5.3)	0.5 (0.5–0.6)	6.9 (5.4–9.5)	1099 (159–19,494)
DT + 2	3.3 (2.9–4.0)	1.9 (1.7–2.5)	0.7 (0.6–1.2)	0.32 (0.24–0.49)	2.6 (1.7–3.7)	0.5 (0.3–0.6)	6.2 (4.1–8.0)	100 (1–20,337)
DT + 3	3.4 (2.7–3.7)	1.5 (1.3–1.9)	1.0 (0.8–1.3)	0.36 (0.28–0.60)	1.6 (1.1–2.2)	0.5 (0.3–0.6)	3.6 (2.8–5.4)	1 (0–305)
Day 35	6.2 (5.2–7.2)	2.8 (2.3–3.3)	2.2 (1.9–3.0)	0.53 (0.44–0.71)	1.2 (0.9–1.3)	0.2 (0.2–0.2)	5.6 (4.1–6.4)	0 (0–0)
p value	< 0.0001	< 0.0001	< 0.0001	0.002	< 0.0001	< 0.0001	< 0.0001	< 0.0001

Data in this table are not normally distributed and shown as median (interquartile range). p values in this table were derived from Friedman tests

an effect of atovaquone–proguanil treatment on the observed changes.

Linear model analysis showed that in the individuals who develop parasitaemia, the leukocyte count remained stable until DT – 1 and then showed a fall, which continued until it reached its nadir on DT + 2, with a median of 3.3×10^5 leukocytes/L. On day DT + 2, a leukocytopenia was observed in 70% (14/20) of the subjects. The absolute neutrophil count started to decrease on DT – 1 to a median value of 1.5×10^5 neutrophils/L on DT + 3. Neutropenia was found in 40% (8/20) of the subjects on this day. A steady fall in absolute lymphocyte count was observed from DT – 2 until DT + 2, when the median lymphocyte count was 0.7×10^5 lymphocytes/L. The percentage of subjects with an absolute lymphocytopenia increased from 30% (6/20) on DT to 70% (14/20) 2 days later. The median absolute monocyte counts remained within the normal range, but showed a mild drop on DT + 2. On day 35 of the study protocol, all parameters had returned to baseline values. The evaluated parameters did not differ significantly between subgroups of subjects infected with NF166.C8 and NF135.C10.

The differential cell count ratios were also found to change significantly over time using the Friedman test (Table 1, Fig. 2). The linear model analysis showed a

gradual rise of the NLCR, reaching a maximum of 4.0 on DT + 1. After DT + 1 a rapid decrease was observed. The MLCR showed a rise from DT – 2 to DT + 1 after which it decreased. The NMCR seemed to show a rise followed by a fall but these changes were not significant in the linear model analysis.

In the four subjects that remained qPCR negative throughout the study period, the differential leukocyte counts remained within normal values and no significant changes in cell counts or cell count ratios were observed. All four received a full course of atovaquone–proguanil at day 13 of the study protocol (Additional file 1: Table S1 and Additional file 3: Figure S2).

Correlations

Significant correlations were found between parasite load and absolute lymphocyte count ($p < 0.001$, correlation coefficient – 0.46) and between parasite load and NLCR ($p < 0.001$, correlation coefficient 0.50) in CHMI-b. Correlations between parasite load and total leukocyte count, MLCR and NMCR were significant, but weak ($p = 0.004$, Spearman’s rho (r_s) – 0.23, $p < 0.001$, r_s 0.36 and $p = 0.003$, r_s 0.23, respectively). There was no significant correlation between parasite load and absolute neutrophil count or absolute monocyte count.




Fig. 2 Changes in differential cell count ratios in the 20 subjects who developed malaria in CHMI-b. The data are shown as medians (dots) and interquartile ranges (whiskers). The data from DT – 2 until DT + 3 were synchronized on DT

Discussion

The present CHMI study shows an increase in total leukocyte, lymphocyte and monocyte count during parasite liver stages of infected subjects. Upon blood stage infection, a decrease is observed in total leukocyte, neutrophil, lymphocyte and monocyte count; these changes clearly relate to the occurrence of blood parasitaemia and are not caused by treatment with atovaquone–proguanil, as shown by the control group of four subjects, who remained non-parasitaemic until day 13 after mosquito exposure and were then treated with a full course of atovaquone–proguanil. Although it cannot be excluded that one or more of these four non-parasitaemic subjects had a liver stage infection when treatment was initiated, we regard it more likely that no sporozoite transmission occurred. In this group, no changes in total or differential leukocyte counts were observed during the study period.

The increase of the total leukocyte count, lymphocytes and monocytes during liver stage development has not been previously reported. During the clinically silent liver phase of malaria, only a relatively low number of hepatocytes become infected and the host immune responses to this stage of the parasite are poorly understood [24]. Previous CHMI studies have studied inflammatory parameters and cellular and humoral immune responses, but only demonstrated changes in these markers during the blood phase of the infection [15–20, 25]. The finding that the total leukocyte count, lymphocyte count and monocyte count show an increase during the liver phase is remarkable and further studies are needed to confirm this finding and to elucidate its underlying pathophysiological mechanism.

The most pronounced change after the liver phase is a fall in lymphocyte count that starts on DT – 1 and reaches its nadir at 0.7×10^5 lymphocytes/L on DT + 2, when 65% of subjects are lymphocytopenic. The neutrophil count only starts to show a significant fall after DT. These changes are reflected in the NLCR, which shows a steep rise to 4.0 on DT + 2. In comparison, in a previous study on patients with imported malaria the median NLCR on admission of all patients was 3.2, and 3.5 in patients with a severe *P. falciparum* infection [12].

Lymphocytopenia has been described in several large cohorts of patients with malaria [9, 26–28] and is highly prevalent in symptomatic travelers with imported malaria [12]. The correlations between parasite and lymphocyte count and between parasite load and NLCR were also demonstrated in a study by Berens-Riha et al. [11], in which patients were stratified

according to their immune status. Both the MLCR and the NLCR were found to be lower in semi-immune patients as compared to non-immune patients. In the present study, all subjects were non-immune. White blood cell count changes have also been described in previous CHMI studies. In a study on clinical manifestations in CHMI with *P. falciparum*, Church et al. described a decrease in total white blood cell count and in neutrophil count, but not in lymphocyte count, with the nadir occurring 2 days after therapy initiation [15]. A decrease in lymphocyte count was observed in several studies involving sporozoite infection after mosquito bite exposure [16–19] and in a study using experimental inoculation with a low number of parasitized erythrocytes [20]. These observations are in line with the findings described here. As no measurements are available between DT + 3 and the end of the study protocol at day 35, we are not able to monitor when the changes observed, started to normalize after treatment. This is an important limitation of the study.

Several mechanisms have been proposed as an explanation for malaria induced lymphocytopenia. A temporary reallocation of lymphocytes has been suggested, which is supported by the observation that lymphocytes rapidly re-emerge in the peripheral circulation after treatment is initiated [29]. Others suggest that the soluble Fas ligand induces apoptosis of lymphocytes, which has been observed both in vitro and in healthy donors from endemic areas [30–34], and a previous CHMI study found an increased production of Granzyme B, which is also known to induce apoptosis, in exposed individuals, [35]. Both mechanisms though might be partly responsible for the observed fall in lymphocyte cell count.

Conclusions

In a setting of controlled human malaria infection in healthy non-immune volunteers, an initial increase of peripheral total leukocyte count and differential lymphocytes and monocytes was observed during liver stage infection of 35 infected volunteers. This rise seems to indicate the presence of a malaria infection and is followed 2–3 days later by the appearance of parasites in the peripheral blood, which is accompanied by a marked decrease in total leukocyte count, lymphocyte count and the neutrophil count and a rise of the NLCR. Both the lymphocyte count and the NLCR correlated with blood parasitaemia, and all parameters had normalized 3–4 weeks after parasite clearance. The non-parasitaemic control group in this study excludes a treatment-related effect.

Additional files

Additional file 1: Table S1. Differential leukocyte counts and their ratios in the 4 non-parasitemic subjects in CHMI-b.

Additional file 2: Figure S1. Changes in total and differential leukocyte counts in the 4 subjects who did not develop malaria in CHMI-b. The data are shown as medians (dots) and interquartile ranges (whiskers). None of the changes in this group were statistically significant.

Additional file 3: Figure S2. Changes in differential cell count ratios in the 4 subjects who did not develop malaria in CHMI-b. The data are shown as medians (dots) and interquartile ranges (whiskers). None of the changes in this group were statistically significant.

Abbreviations

CHMI: controlled human malaria infection; NLCR: neutrophil to lymphocyte count ratio; MLCR: monocyte to lymphocyte count ratio; NMCR: neutrophil to monocyte count ratio; qPCR: quantitative polymerase chain reaction.

Authors' contributions

MEvW was responsible for the data analysis and writing of the manuscript. MCCL, CCH, RWS, JJVH and PJVG contributed to the writing and revising of the manuscript. MCCL, LJW, CCH, RWS, JJVH and PJVG were involved in the collection of clinical data. RK was responsible for collection of patient data and database management. All authors read and approved the final manuscript.

Author details

¹ Institute for Tropical Diseases, Harbour Hospital, Rotterdam, The Netherlands. ² Department of Medical Microbiology and Infectious Diseases, Erasmus MC and Harbour Hospital, Rotterdam, The Netherlands. ³ Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands. ⁴ Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands.

Acknowledgements

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The datasets analysed during the current study are available from the corresponding author on reasonable request.

Consent for publication

Is regulated within informed consent procedure of participating volunteers.

Ethics approval and consent to participate

These studies were approved by the Netherlands' Central Committee on Human Research (CCMO NL41004.078.12 and NL48704.000.14, respectively) and are registered with ClinicalTrials.gov (Registration Numbers NCT01627951 and NCT02149550, respectively) [4].

Funding

The CHMI studies described here were supported by Top Institute Pharma [Grant T4-102] and the Bill and Melinda Gates Foundation [Grant opp1080385], respectively. The Port of Rotterdam supported the Harbour Hospital with a grant to study infectious diseases in the region of Rotterdam, the Netherlands. Neither financial sponsor was involved in the respective study design, in the collection, analysis or interpretation of data, or in the writing of the report or in the decision to submit for publication.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 6 July 2017 Accepted: 4 November 2017

Published online: 10 November 2017

References

- Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human challenge infections can accelerate clinical malaria vaccine development. *Nat Rev Immunol*. 2011;11:57–64.
- Sulyok M, Ruckle T, Roth A, Murbeth RE, Chalons S, Kerr N, et al. DSM265 for *Plasmodium falciparum* chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection. *Lancet Infect Dis*. 2017;17:636–44.
- Su XZ. Tracing the geographic origins of *Plasmodium falciparum* malaria parasites. *Pathog Glob Health*. 2014;108:261–2.
- McCall MMB, Wammes LJ, Langenberg MCC, van Gemert GJ, Walk J, Hermsen CC, et al. Infectivity of *Plasmodium falciparum* sporozoites determines emerging in a primary malaria infection. *Sci Transl Med*. 2017;9:eaag2490.
- Teirlinck AC, Roestenberg M, van de Vegte-Bolmer M, Scholzen A, Heinrichs MJ, Siebelink-Stoter R, et al. NF135.C10: a new *Plasmodium falciparum* clone for controlled human malaria infections. *J Infect Dis*. 2013;207:656–60.
- Eldering M, Morlais I, van Gemert GJ, van de Vegte-Bolmer M, Graumans W, Siebelink-Stoter R, et al. Variation in susceptibility of African *Plasmodium falciparum* malaria parasites to TEP1 mediated killing in *Anopheles gambiae* mosquitoes. *Sci Rep*. 2016;6:20440.
- Lisse IM, Aaby P, Whittle H, Knudsen K. A community study of T lymphocyte subsets and malaria parasitaemia. *Trans R Soc Trop Med Hyg*. 1994;88:709–10.
- Kassa D, Petros B, Mesele T, Hailu E, Wolday D. Characterization of peripheral blood lymphocyte subsets in patients with acute *Plasmodium falciparum* and *P. vivax* malaria infections at Wonji Sugar Estate, Ethiopia. *Clin Vaccine Immunol*. 2006;13:376–9.
- Richards MW, Behrens RH, Doherty JF. Hematologic changes in acute, imported *Plasmodium falciparum* malaria. *Am J Trop Med Hyg*. 1998;59:859.
- Ladhani S, Lowe B, Cole AO, Kowuondo K, Newton CR. Changes in white blood cells and platelets in children with falciparum malaria: relationship to disease outcome. *Br J Haematol*. 2002;119:839–47.
- Berens-Riha N, Kroidl I, Schunk M, Alberer M, Beissner M, Pritsch M, et al. Evidence for significant influence of host immunity on changes in differential blood count during malaria. *Malar J*. 2014;13:155.
- van Wolfswinkel ME, Vliegenthart-Jongbloed K, Melo MD, Wever PC, McCall MB, Koelewijn R, et al. Predictive value of lymphocytopenia and the neutrophil-lymphocyte count ratio for severe imported malaria. *Malar J*. 2013;12:101.
- Herbinger KH, Hanus I, Beissner M, Berens-Riha N, Kroidl I, von Sonnenburg F, et al. Lymphocytosis and lymphopenia induced by imported infectious diseases: a controlled cross-sectional study of 17,229 diseased German travelers returning from the tropics and subtropics. *Am J Trop Med Hyg*. 2016;94:1385–91.
- Zahorec R. Ratio of neutrophil to lymphocyte counts—rapid and simple parameter of systemic inflammation and stress in critically ill. *Bratisl Lek Listy*. 2001;102:5–14.
- Church LW, Le TP, Bryan JP, Gordon DM, Edelman R, Fries L, et al. Clinical manifestations of *Plasmodium falciparum* malaria experimentally induced by mosquito challenge. *J Infect Dis*. 1997;175:915–20.
- Rzepczyk CM, Stamatou S, Anderson K, Stowers A, Cheng Q, Saul A, et al. Experimental human *Plasmodium falciparum* infections: longitudinal analysis of lymphocyte responses with particular reference to gamma delta T cells. *Scand J Immunol*. 1996;43:219–27.
- De Mast Q, Sweep FC, McCall M, Geurts-Moespot A, Hermsen C, Calandra T, et al. A decrease of plasma macrophage migration inhibitory factor concentration is associated with lower numbers of circulating lymphocytes in experimental *Plasmodium falciparum* malaria. *Parasite Immunol*. 2008;30:133–8.
- Scholzen A, Teirlinck AC, Bijker EM, Roestenberg M, Hermsen CC, Hoffman SL, et al. BAFF and BAFF receptor levels correlate with B cell subset activation and redistribution in controlled human malaria infection. *J Immunol*. 2014;192:3719–29.
- Verhage DF, Telgt DS, Bousema JT, Hermsen CC, van Gemert GJ, van der Meer JW, et al. Clinical outcome of experimental human malaria induced by *Plasmodium falciparum*-infected mosquitoes. *Neth J Med*. 2005;63:52–8.

20. Woodberry T, Minigo G, Piera KA, Amante FH, Pinzon-Charry A, Good MF, et al. Low-level *Plasmodium falciparum* blood-stage infection causes dendritic cell apoptosis and dysfunction in healthy volunteers. *J Infect Dis*. 2012;206:333–40.
21. Bijker EM, Schats R, Obiero JM, Behet MC, van Gemert GJ, van de Vegte-Bolmer M, et al. Sporozoite immunization of human volunteers under mefloquine prophylaxis is safe, immunogenic and protective: a double-blind randomized controlled clinical trial. *PLoS ONE*. 2014;9:e112910.
22. van Meer MP, Bastiaens GJ, Boulaksil M, de Mast Q, Gunasekera A, Hoffman SL, et al. Idiopathic acute myocarditis during treatment for controlled human malaria infection: a case report. *Malar J*. 2014;13:38.
23. Coffeng LE, Hermsen CC, Sauerwein RW, de Vlas SJ. The power of malaria vaccine trials using controlled human malaria infection. *PLoS Comput Biol*. 2017;13:e1005255.
24. Bertolino P, Bowen DG. Malaria and the liver: immunological hide-and-seek or subversion of immunity from within? *Front Microbiol*. 2015;6:41.
25. Obiero JM, Shekalaghe S, Hermsen CC, Mpina M, Bijker EM, Roestenberg M, et al. Impact of malaria preexposure on antiparasite cellular and humoral immune responses after controlled human malaria infection. *Infect Immun*. 2015;83:2185–96.
26. McKenzie FE, Prudhomme WA, Magill AJ, Forney JR, Permpantich B, Lucas C, et al. White blood cell counts and malaria. *J Infect Dis*. 2005;192:323–30.
27. Kotepui M, Phunphuech B, Phiwklam N, Chupeerach C, Duangmano S. Effect of malarial infection on haematological parameters in population near Thailand–Myanmar border. *Malar J*. 2014;13:218.
28. Olliaro P, Djimde A, Dorsey G, Karema C, Martensson A, Ndiaye JL, et al. Hematologic parameters in pediatric uncomplicated *Plasmodium falciparum* malaria in sub-Saharan Africa. *Am J Trop Med Hyg*. 2011;85:619–25.
29. Hviid L, Kurtzhals JAL, Goka BQ, OliverCommy JO, Nkrumah FK, Theander TG. Rapid reemergence of T cells into peripheral circulation following treatment of severe and uncomplicated *Plasmodium falciparum* malaria. *Infect Immun*. 1997;65:4090–3.
30. Kemp K, Akanmori BD, Adabayeri V, Goka BQ, Kurtzhals JAL, Behr C, et al. Cytokine production and apoptosis among T cells from patients under treatment for *Plasmodium falciparum* malaria. *Clin Exp Immunol*. 2002;127:151–7.
31. Kemp K, Akanmori BD, Hviid L. West African donors have high percentages of activated cytokine producing T cells that are prone to apoptosis. *Clin Exp Immunol*. 2001;126:69–75.
32. Balde AT, Sarthou JL, Roussilhon C. Acute *Plasmodium falciparum* infection is associated with increased percentages of apoptotic cells. *Immunol Lett*. 1995;46(1–2):59–62.
33. Toure Balde A, Sarthou JL, Aribot G, Michel P, Trape JF, Rogier C, et al. *Plasmodium falciparum* induces apoptosis in human mononuclear cells. *Infect Immun*. 1996;64:744–50.
34. Kern P, Dietrich M, Hemmer C, Wellinghausen N. Increased levels of soluble Fas ligand in serum in *Plasmodium falciparum* malaria. *Infect Immun*. 2000;68:3061–3.
35. Bijker EM, Teirlinck AC, Schats R, van Gemert GJ, van de Vegte-Bolmer M, van Lieshout L, et al. Cytotoxic markers associate with protection against malaria in human volunteers immunized with *Plasmodium falciparum* sporozoites. *J Infect Dis*. 2014;210:1605–15.

Submit your next manuscript to BioMed Central
and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

